In the past, thalidomide has caused devastating birth defects. For this reason its
use is carefully regulated under a risk management programme designed to prevent
exposing unborn babies to thalidomide.
This programme is called the Pregnancy Prevention Programme and was a
mandatory requirement before thalidomide could be considered for approval by the
regulatory authorities. It is under the responsibility of Celgene Ltd, the company that
markets thalidomide, to ensure that all prescriptions of thalidomide are controlled.
You can contact Celgene directly via their website at: – http://www.celgene.co.uk/
If you have any questions please feel free to contact me by email to askthenurse@myeloma.org.uk or on the freephone Myeloma Infoline on 0800 980 3332
Best wishes
Ellen